MRK Stock Price Today (September 2026) — Merck & Co., Inc. Analysis & Key Metrics 2026-09-03
Merck & Co., Inc. (MRK) is trading at $152.34, up 0.46% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $135.38 (-11.1% upside).
- Volatility remains elevated (48.19% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.10% YoY) alongside significant competitive pressures.
MRK Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Merck & Co., Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $412.83B
P/E Ratio
Forward P/E: 15.48
Revenue Growth
Year over Year
Analyst Target
+-11.1% upside potential
Key Investor Questions About MRK
What investors need to know before buying
Based on current market data, MRK presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 66.35)
- Fundamentals say: Caution warranted (high leverage concerns)
MRK's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRK investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $53.91B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, MRK stock traded between $77.58 and $156.92—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 48.19% annualized volatility and β=0.42, the stock exhibits low sensitivity to market moves—making MRK suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning
Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One
Novartis just committed billions not to discover a new drug but to change how an existing one enters your body. The reason why that quiet engineering bet could matter more than a blockbuster pipeline win is buried in the fine print.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Explore More Analysis for MRK
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Merck & Co., Inc.
Merck & Co., Inc. (MRK) is currently trading at $152.34. The RSI (14-day) is at 66.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $135.38 implies 11.1% downside from current levels. Volatility is high at 48.2% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Merck & Co., Inc. (MRK): The trailing P/E ratio is 121.87, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.48, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 10.26, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 8.97. Price-to-Sales is 5.65. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering MRK, the consensus price target is $135.38. This represents a 11.1% downside from the current price of $152.34. The range spans from a low target of $105.00 to a high target of $155.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Merck & Co., Inc. (MRK) pays a dividend with a current yield of approximately 2.23%. The annualized dividend rate is $3.32 per share. The payout ratio is 268.8%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-09-15T00:00:00.000Z.
Key risks for Merck & Co., Inc. (MRK) investors include: 1. High volatility (48.2% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 128.41) which could pressure margins in a rising rate environment. 3. Unsustainable dividend payout ratio (269%) could lead to a dividend cut. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Merck & Co., Inc.'s (MRK) current debt and financial health profile: Total debt stands at $53.91B. The debt-to-equity ratio is 128.41, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.32, indicating adequate short-term liquidity. The quick ratio is 0.74. The company holds $7.14B in cash and equivalents. Free cash flow is positive at $15.17B, providing a cushion for debt servicing and shareholder returns.